Jim Simons Gain Therapeutics, Inc. Transaction History
Renaissance Technologies LLC
- $63.1 Billion
- Q3 2024
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 53,264 shares of GANX stock, worth $83,091. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,264
Previous 118,700
55.13%
Holding current value
$83,091
Previous $151,000
37.75%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding GANX
# of Institutions
23Shares Held
2.39MCall Options Held
10KPut Options Held
0-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$917,9190.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$883,1620.04% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny335KShares$521,9630.01% of portfolio
-
Geode Capital Management, LLC Boston, MA272KShares$424,2760.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA145KShares$226,5380.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $18.5M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...